1. A novel framework to assess haematology and oncology registration trials: The THEOREMM project
- Author
-
Olivier, Timothée, Haslam, Alyson, Burke, Patricia, Boutron, Isabelle, Naudet, Florian, Ioannidis, John PA, and Prasad, Vinay
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,8.4 Research design and methodologies (health services) ,Good Health and Well Being ,Humans ,Medical Oncology ,Hematology ,Clinical Trials as Topic ,Research Design ,Randomized Controlled Trials as Topic ,Neoplasms ,appraisal ,framework ,haematology ,metaresearch ,oncology ,trials ,Clinical Sciences ,General Clinical Medicine ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundMethodological limitations affect a significant number of oncology and haematology trials, raising concerns about the applicability of their results. For example, a suboptimal control arm or limited access to best care upon progression may skew the trial results toward a benefit in the experimental arm. Beyond the fact that such limitations do not prevent drugs reaching the market, other assessment tools, such as those developed by professional societies-ESMO-MCBS and ASCO Value Framework-do not integrate these important shortcomings.MethodsWe propose creating a novel framework with the scope of assessing registration cancer clinical trials in haematology and oncology (randomized or single arm)-that is trials leading to a marketing authorization. The main steps of the methods are (1) assembling a scientific board; (2) defining the scope, goal and methods through pre-specified, pre-registered and protocolized methodology; (3) preregistration of the protocol; (4) conducting a scoping review of limitations and biases affecting oncology trials and assessing existing scores or methods; (5) developing a list of features to be included and assessed within the framework; (6) assessing each feature through a questionnaire sent to highly cited haematologists and oncologists involved in clinical trials; and (7) finalizing the first version of framework.ResultsNot applicable.ConclusionsOur proposal emerged in response to the lack of consideration for key limitations in current trial assessments. The goal is to create a framework specifically designed to assess single trials leading to marketing authorization in the field of oncology and haematogy.
- Published
- 2024